Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.
作者信息
Thijssen Rachel, Slinger Erik, Weller Katinka, Geest Christian R, Beaumont Tim, van Oers Marinus H J, Kater Arnon P, Eldering Eric
机构信息
Department of Experimental Immunology, Academic Medical Center, University of Amsterdam Department of Hematology, Academic Medical Center, University of Amsterdam.
Department of Experimental Immunology, Academic Medical Center, University of Amsterdam.
出版信息
Haematologica. 2015 Aug;100(8):e302-6. doi: 10.3324/haematol.2015.124560. Epub 2015 May 8.
Abstract
摘要
相似文献
1
Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.慢性淋巴细胞白血病中由微环境信号诱导产生的对ABT-199的耐药性可被CD20抗体或激酶抑制剂抵消。
Haematologica. 2015 Aug;100(8):e302-6. doi: 10.3324/haematol.2015.124560. Epub 2015 May 8.
2
ABT-199 for chronic lymphocytic leukemia.用于慢性淋巴细胞白血病的ABT-199
Clin Adv Hematol Oncol. 2014 Oct;12(10):698-700.
3
Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.维奈托克：抑制Bcl-2用于治疗慢性淋巴细胞白血病。
Drugs Today (Barc). 2016 Apr;52(4):249-60. doi: 10.1358/dot.2016.52.4.2470954.
4
Venetoclax (Venclexta) for chronic lymphocytic leukemia.维奈克拉（维可来）用于治疗慢性淋巴细胞白血病。
Med Lett Drugs Ther. 2016 Aug 1;58(1500):101-2.
5
Suzanne Cory: Life-and-Death Switches: the Rise of BH3 Mimetics.苏珊娜·科里：生死开关：BH3模拟物的崛起
Trends Cancer. 2016 Oct;2(10):537-539. doi: 10.1016/j.trecan.2016.09.009. Epub 2016 Oct 13.
6
Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia.维奈克拉，首款用于慢性淋巴细胞白血病患者的BCL-2抑制剂。
Clin Adv Hematol Oncol. 2019 Aug;17(8):440-443.
7
High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.高内涵筛选鉴定出可克服活化慢性淋巴细胞白血病（CLL）细胞中维奈托克耐药性的激酶抑制剂。
Blood. 2016 Aug 18;128(7):934-47. doi: 10.1182/blood-2015-12-687814. Epub 2016 Jun 13.
8
A BH3 Mimetic for Killing Cancer Cells.一种用于杀死癌细胞的 BH3 模拟物。
Cell. 2016 Jun 16;165(7):1560. doi: 10.1016/j.cell.2016.05.080.
9
ABT-199 shows effectiveness in CLL.ABT-199 在 CLL 中显示出疗效。
Cancer Discov. 2014 Sep;4(9):OF7. doi: 10.1158/2159-8290.CD-NB2014-102. Epub 2014 Jul 3.
10
Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.用BH3模拟物靶向BCL2：维奈托克在慢性淋巴细胞白血病及相关B细胞恶性肿瘤中的基础科学与临床应用
Clin Pharmacol Ther. 2017 Jan;101(1):89-98. doi: 10.1002/cpt.553. Epub 2016 Nov 26.
引用本文的文献
1
The Role of Tumor Microenvironment and Targeted Therapy in Chronic Lymphocytic Leukemia.肿瘤微环境与靶向治疗在慢性淋巴细胞白血病中的作用
Curr Issues Mol Biol. 2025 Aug 1;47(8):604. doi: 10.3390/cimb47080604.
2
CD86, the double agent: Significance of CD86 expression in B-cell malignancies.CD86，双面特工：CD86在B细胞恶性肿瘤中的表达意义
Int J Cancer. 2025 Nov 1;157(9):1772-1780. doi: 10.1002/ijc.70028. Epub 2025 Jul 10.
3
Venetoclax synergizes with Wnt/β-catenin inhibitor C-82 in acute myeloid leukemia by increasing the degradation of Mcl-1 protein.维奈托克通过增加Mcl-1蛋白的降解，与Wnt/β-连环蛋白抑制剂C-82在急性髓系白血病中发挥协同作用。
Cancer Cell Int. 2025 May 29;25(1):197. doi: 10.1186/s12935-025-03825-8.
4
G-protein coupled receptor kinase-2 regulates the migration of chronic lymphocytic leukaemia cells to sphingosine-1 phosphate in vitro and their trafficking in vivo.G蛋白偶联受体激酶2在体外调节慢性淋巴细胞白血病细胞向1-磷酸鞘氨醇的迁移以及在体内的运输。
Sci Rep. 2025 Feb 24;15(1):6530. doi: 10.1038/s41598-025-91536-5.
5
Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice.依鲁替尼与维奈托克联合治疗慢性淋巴细胞白血病：实际中的协同作用
Blood Neoplasia. 2024 Sep;1(3). doi: 10.1016/j.bneo.2024.100034. Epub 2024 Aug 1.
6
BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies.血液系统恶性肿瘤中的BCL-2抑制剂：预测反应的生物标志物及管理策略
Front Oncol. 2025 Jan 21;14:1501950. doi: 10.3389/fonc.2024.1501950. eCollection 2024.
7
BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism.在活跃的慢性淋巴细胞白血病克隆扩增过程中，BCL2蛋白逐渐下降：对维奈托克临床疗效的潜在影响及机制洞察
Lymphatics. 2024 Jun;2(2):50-78. doi: 10.3390/lymphatics2020005. Epub 2024 Mar 28.
8
Targeting splicing for hematological malignancies therapy.针对血液系统恶性肿瘤的治疗进行剪接靶向。
BMC Genomics. 2024 Nov 11;25(1):1067. doi: 10.1186/s12864-024-10975-y.
9
Profiling protein-protein interactions to predict the efficacy of B-cell-lymphoma-2-homology-3 mimetics for acute myeloid leukaemia.分析蛋白质-蛋白质相互作用，预测 B 细胞淋巴瘤-2 同源物-3 模拟物对急性髓系白血病的疗效。
Nat Biomed Eng. 2024 Nov;8(11):1379-1395. doi: 10.1038/s41551-024-01241-3. Epub 2024 Jul 18.
10
Metabolic signature and response to glutamine deprivation are independent of p53 status in B cell malignancies.在B细胞恶性肿瘤中，代谢特征和对谷氨酰胺剥夺的反应与p53状态无关。
iScience. 2024 Mar 28;27(5):109640. doi: 10.1016/j.isci.2024.109640. eCollection 2024 May 17.
本文引用的文献
1
Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma.淋巴瘤中 BCL2 家族蛋白获得性突变导致对 BH3 模拟物 ABT-199 的耐药性。
Blood. 2014 Jun 26;123(26):4111-9. doi: 10.1182/blood-2014-03-560284. Epub 2014 Apr 30.
2
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.依鲁替尼，一种磷酸肌醇 3-激酶 p110δ 的抑制剂，用于治疗复发/难治性慢性淋巴细胞白血病。
Blood. 2014 May 29;123(22):3390-7. doi: 10.1182/blood-2013-11-535047. Epub 2014 Mar 10.
3
Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor.分子通路：慢性淋巴细胞白血病微环境靶向治疗——聚焦 B 细胞受体。
Clin Cancer Res. 2014 Feb 1;20(3):548-56. doi: 10.1158/1078-0432.CCR-13-0226. Epub 2013 Dec 9.
4
IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells.自体 T 细胞的 IL-21 和 CD40L 信号可诱导 CLL 细胞的抗原非依赖性增殖。
Blood. 2013 Oct 24;122(17):3010-9. doi: 10.1182/blood-2012-11-467670. Epub 2013 Sep 6.
5
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.伊布替尼治疗复发慢性淋巴细胞白血病的 BTK 靶点。
N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19.
6
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.ABT-199，一种强效和选择性的 BCL-2 抑制剂，在发挥抗肿瘤活性的同时不影响血小板。
Nat Med. 2013 Feb;19(2):202-8. doi: 10.1038/nm.3048. Epub 2013 Jan 6.
7
Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.使 Noxa/Mcl-1 平衡向有利于 Noxa 的方向倾斜可克服慢性淋巴细胞白血病中 ABT-737 的耐药性。
Clin Cancer Res. 2012 Jan 15;18(2):487-98. doi: 10.1158/1078-0432.CCR-11-1440. Epub 2011 Nov 29.
8
CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101.CD40 刺激使 CLL 细胞对 II 型抗 CD20 mAb GA101 诱导的溶酶体细胞死亡敏感。
Blood. 2011 Nov 10;118(19):5178-88. doi: 10.1182/blood-2011-01-331702. Epub 2011 Sep 26.
9
CD40 stimulation sensitizes CLL cells to rituximab-induced cell death.CD40 刺激使 CLL 细胞对利妥昔单抗诱导的细胞死亡敏感。
Leukemia. 2011 Jun;25(6):968-78. doi: 10.1038/leu.2011.39. Epub 2011 Mar 15.
10
Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering.在 CD40/TLR9 触发后，IgH 突变与未突变 CLL 细胞中 NF-κB 信号和化疗耐药性的二分法。
Oncogene. 2010 Sep 9;29(36):5071-82. doi: 10.1038/onc.2010.248. Epub 2010 Jun 28.
Zotero 插件